|
Oklahoma
State Senate
Communications Division
State Capitol
Oklahoma City, OK 73105
For Immediate Release: June 16, 2015
Rep. Richard Morrissette and Sen. Rob Standridge pose with Gov.
Mary Fallin
after the recent ceremonial signing of House Bill 1074.
Standridge says Right-to-Try Act will empower terminally-ill
patients
Gov. Fallin recently held a ceremonial signing of
House Bill 1074, also known as the Right-to-Try Act, by Rep. Richard
Morrissette and Sen. Rob
Standridge. The new law, which goes into effect November 1,
2015, will allow terminally-ill patients, who have received approval
from their physician, access to investigational medications, biological
products or devices that have completed Food and Drug Administration
phase one safety testing and remain under an approved investigation.
“This new law will give terminally-ill patients the right
to try to save their own life by giving them more control over their
treatment options,” said Standridge, R-Norman. “Until
now, these patients’ hands have been tied by restrictive laws
in our state on investigational treatments and they just had to
accept their fate. Oklahoma was taking a basic human right away
from terminally-ill patients by not allowing them to fight for their
life but House Bill 1074 will change that in November.”
Right-to-Try has been adopted in twenty states including Arizona,
Colorado, Michigan, Missouri and, most recently, Florida.
Under HB 1074, manufacturers will not be required to make experimental
treatments available to eligible patients. Health insurance companies
will not be required to provide coverage for such products either.
A licensing board cannot take action against a provider based solely
on their recommendations to an eligible patient regarding access
to, or treatment with, such products. Additionally, the new law
will not create a private cause of action against a manufacturer
or against any other person or entity involved in the care of an
eligible patient using such products.
For more information, contact:
Sen.
Standridge: 405-521-5535
|
